Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used in the treatment of non-small cell lung cancer (NSCLC). However, erlotinib resistance leads to high mortality in patients with NSCLC, while the activation of STAT3 is closely related to erlotinib re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaowen, Liu, Bojia, Ning, Qing, Xia, Zhi, Zhong, Rongling, Zhang, Li, Wu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709830/
https://www.ncbi.nlm.nih.gov/pubmed/33200228
http://dx.doi.org/10.3892/or.2020.7848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709830/
https://www.ncbi.nlm.nih.gov/pubmed/33200228
http://dx.doi.org/10.3892/or.2020.7848

Ejemplares similares